ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement

Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric Cas-CLOVER. DUBLIN and DALLAS, Sept. 14, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio…